• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau,

New Delhi, July 25 The less than a year old Ipca Laboratories and Ranbaxy Pharmaceuticals alliance has received its fourth US Food and Drugs Administration approval for three strengths of hydrochlorothiazide tablets.

The drugs will be manufactured initially at Ohm Laboratories, Ranbaxy’s Princeton-based facility, and marketed in the US healthcare system using the Ipca’s DMF approved active pharmaceutical ingredient (API) — hydrochlorothiazide.

The formulation is used as an adjunct therapy oedema, and the company claims the total annual market sales for the tablets in the US were $30.8 million during the last financial year.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Reva launches upgraded version

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line